Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-08-01

Study Completion Date

2026-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a chart review of data on use of antiplatelet (AP) medications for acute coronary syndrome in the ER. Guidelines recommend giving aspirin in the ER and a second AP agent in the cath lab. What is the outcome when the 2 agents are given n the ER?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

NCT06710184

NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI) Acute Myocardial Infarction (AMI)

RECRUITING PHASE4

What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

NCT04436978

Acute Coronary Syndrome Myocardial Infarction Atrial Fibrillation +8 more

RECRUITING PHASE4

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

NCT01952392

Acute Coronary Syndrome

COMPLETED

Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients

NCT05125276

Non ST Segment Elevation Acute Coronary Syndrome

UNKNOWN PHASE4

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study

NCT04609111

Acute Coronary Syndrome

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Dual antiplatelet therapy (DAPT) is a standard treatment in ST-elevation myocardial infarction (STEMI) and non-ST-segment-elevation acute coronary syndrome (NSTEACS) . However, the timing of initiation of DAPT in the Emergency Department (ED) has been defined by recent western guidelines (i.e., aspirin in the ER and and a second AP agent when the coronary anatomy has been denied in the cath lab. This strategy aims at decreasing the incidence of bleeding events. However, patients with ACS in the Middle East are younger than those in the West and have lower bleeding risk. The purpose of this study is to evaluate the incidence of major bleeding in patients who received DAPT in the ED according to the discretion of the treating physician.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Bleeding Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adult patients admitted for acute coronary syndrome via the ED

Patients with ACS presenting to the ED with a planned coronary angiography for possible coronary revascularization who get aspirin in the ED will be evaluated for bleeding and major cardiovascular events when they receive a second antiplatelet agent in the ED compared with in the cath lab.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients
* Presenting with acute coronary syndrome (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, and unstable angina).
* Antiplatelet medication (s) prescribed during index admission to hospital.
* Willingness of the patient to be called for follow up up to 1 year after index hospitalization.